CAPLIPOINT Caplin Point Laboratories Q2 FY26 results (Jul–Sep 2025) and concall
Caplin Point Laboratories delivered a strong Q2 & H1 FY26, with operating revenue growing 11% YoY and PAT increasing 21.6% to 28.3% of revenue, surpassing their 25% target. The company highlighted its unique asset-light business model, focus on smaller Latin American markets, and strategic backward integration efforts. Significant progress was noted in US operations, with Caplin Steriles US achieving profitability ahead of schedule, and a robust pipeline of ANDAs and new product filings across various geographies. Management emphasized prudent capital allocation, with no debt and substantial l
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 10.6%, net profit up 22.1% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 483 | 493 | 502 | 510 | 534 +11% |
| EBITDA | 165 | 162 | 168 | 178 | 189 +15% |
| Net profit | 131 | 140 | 145 | 151 | 160 +22% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
